Paraneoplastic Movement Disorders

Movement Disorders

Volumn 24, Issue 12, 2009, Pages 1715-1724

  Grant, Robin ^a   Graus, Francesc ^b  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Cerebellar; Chorea; Myoclonus; Opsoclonus; Paraneoplastic; Parkinson; Stiff person

Indexed keywords

4 AMINOBUTYRIC ACID; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CD20 ANTIBODY; CORTICOTROPIN; DANTROLENE; DEXAMETHASONE; GABAPENTIN; GLUTAMATE DECARBOXYLASE; HU ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; METABOTROPIC RECEPTOR 1 ANTIBODY; METHYLPREDNISOLONE; PHENYTOIN; RECEPTOR ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANTIBODY BLOOD LEVEL; AUTOIMMUNE DISEASE; CEREBELLAR ATAXIA; CEREBELLUM DEGENERATION; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DRUG MEGADOSE; EXTRAPYRAMIDAL SYNDROME; HUMAN; IMMUNOTHERAPY; MOTOR DYSFUNCTION; MYOTONIA; NEUROLOGIC DISEASE; OPSOCLONUS MYOCLONUS SYNDROME; PARANEOPLASTIC SYNDROME; PARKINSONISM; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; STIFF MAN SYNDROME; THERAPY RESISTANCE;

AUTOANTIBODIES; BRAIN DISEASES; HUMANS; MOVEMENT DISORDERS; PARANEOPLASTIC SYNDROMES;

EID: 70449924195     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22658     Document Type: Review

References (79)

1. Pittock SJ, Kryzer TJ, Lennon VA. Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol 2004;56:715-719.
2. Roberts WK, Darnell RB. Neuroimmunology of paraneoplastic neurological degenerations. Curr Opin Immunol 2004;16:616-622.
3. Graus F, Lang B, Pozo-Rosich P, Saiz A, Casamitjana R, Vincent A. P/Q type calcium channel antibodies in paraneoplastic cerebellar degeneration with lung cancer. Neurology 2002;59:764-766.
4. Coesmans M, Sillevis Smitt PA, Linden DJ, et al. Mechanisms underlying cerebellar motor deficits due to mGluR1-autoantibodies. Ann Neurol 2003;53:325-336. (Pubitemid 36258636)
5. Dalmau J, Tüzün E, Wu HY, et al. Paraneoplastic anti-N-methyl- D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007;61:25-36. (Pubitemid 46214241)
6. Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004;75:1135-1140. (Pubitemid 39005770)
7. Linke R, Schroeder M, Helmberger T, Voltz R. Antibody positive paraneoplastic neurological syndromes: value of CT and PET for tumor diagnosis. Neurology 2004;63:282-286 (Pubitemid 38971127)
8. Vedeler CA, Antoine JC, Giometto B, et al. Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. Eur J Neurol 2006;13:682-690. (Pubitemid 44139368)
9. Shams'ili S, Grefkens J, de Leeuw B, et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain 2003;126:1409-1418.
10. Hammack JE, Kotanides H, Rosenblum MK, Posner JB. Paraneoplastic cerebellar degeneration: clinical and immunological findings in 21 patients with Hodgkin's disease. Neurology 1992;42:1938-1943.
11. Nakao YK, Motomura M, Fukudome T, et al. Seronegative Lambert- Eaton myasthenic syndrome: study of 110 Japanese patients. Neurology 2002;59:1773-1775. (Pubitemid 35424462)
12. Bernal F, Shams'ili S, Rojas I, et al. Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease. Neurology 2003;60:230-234.
13. Mason WP, Graus F, Lang B, et al. Small cell lung cancer, paraneoplastic cerebellar degeneration and Lambert-Eaton Myasthenic Syndrome. Brain 1997;120:1279-1300. (Pubitemid 27344700)
14. Petersen K, Rosenblum MK, Kotanides H, Posner JB. Paraneoplastic cerebelaar degeneration: a clinical analysis of 55 anti-Yo antibody positive patients. Neurology 1992;42:1931-1937.
15. Lucchinetti CF, Kimmel DW, Lennon VA. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear auto-antibodies. Neurology 1998;50:652-657. (Pubitemid 28146144)
16. Graus F, Keime-Guibert F, Rene R, et al. Anti-Hu associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001;124:1138-1148. (Pubitemid 32510382)
17. Chan KH, Vernino S, Lennon VA. ANNA-3 antineuroanl nuclear antibody: marker of lung cancer related autoimmunity. Ann Neurol 2001;50:301-311. (Pubitemid 32848732)
18. Vernino S, Tuite P, Adler CH, et al. Paraneoplastic chorea associated with CRMP-5 neuronal autoantibody and lung carcinoma. Ann Neurol 2002;51:625-630.
19. de la Sayette V, Bertran F, Honnorat J, Schaeffer S, Iglesias S, Defer G. Paraneoplastic cerebellar syndrome and optic neuritis with anti-cv2 antibodies. Arch Neurol 1998;55:405-408.
20. Yu Z, Kryzer TJ, Griesmann GE, Kim K, Benarroch EE, Lennon VA. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity Ann Neurol 2001;49:146-154.
21. Honnorat J, Antoine JC, Derrington E, Aguera M, Belin MF. Antibodies to a paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 1996;61:270-276.
22. Uchya M, Graus F, Rene R, Delattre JY. Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies. J Neurol Neurosurg Psychiatry 1996;60:388-392. (Pubitemid 26118745)
23. Counsell C, McLeod M, Grant R. Reversal of subacute paraneoplastic cerebellar syndrome with intravenous immunoglobulin. Neurol 1994;44:1184-1185. (Pubitemid 24188205)
24. Wong A. An update on opsoclonus. Curr Opin Neurol 2007;20:25-31.
25. Rudnick E, Khakoo Y, Antunes NL, et al. Opsoclonus-Myoclonus- Ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the children's cancer group study. Med Pediatr Oncol 2001;36:612-622. (Pubitemid 32402157)
26. Mitchell WG, Davalos-Gonzalez Y, Brumm VL, et al. Opsoclonus- ataxia caused by childhood neuroblastoma: developmental and neurological sequelae. Pediatrics 2002;109:86-98. (Pubitemid 34049431)
27. Bataller L, Graus F, Saiz A, Vilchez JJ. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain 2001;124:437-443. (Pubitemid 32142415)
28. Ohara S, Iijima N, Hayashida K, Oide T, Katai S. Autopsy case of opsoclonus-myoclonus-ataxia and cerebellar cognitive affective syndrome associated with small cell carcinoma of the lung. Mov Disord 2007;22:1320-1324. (Pubitemid 47325042)
29. Baets J, Pals P, Bergmans B, et al. Opsoclonus-myoclonus syndrome: a colinicopathological confrontation. Acta Neurol Belg 2006;106:142-146.
30. Giordana MT, Soffietti R, Schiffer D. Paraneoplastic opsoclonus: a neuropathologic study of two cases. Clin Neuropathol 1989;8:295-300. (Pubitemid 20101118)
31. Ridley A, Kennard C, Scholtz CL, Büttner-Ennever JA, Summers B, Turnbull A. Omnipause neurons in two cases of opsoclonus associated with oat cell carcinoma of the lung. Brain 1987;110:1699-1709. (Pubitemid 18152602)
32. Pranzatelli MR, Tate ED, Wheeler A, et al. Screening for autoantibodies in children with opsoclonus myoclonus ataxia. Pediatr Neurol 2002;27:384-387. (Pubitemid 36034275)
33. Bataller L, Rosenfeld MR, Graus F, Vilchez JJ, Cheung NK, Dalmau J. Autoantigen diversity in the opsoclonus-myoclonus syndrome. Ann Neurol 2003;53:347-353.
34. Caviness JN, Forsyth PA, Layton DD, McPhee TJ. The movement disorder of adult opsoclonus. Mov Disord 1995;10:22-27.
35. Martino D, Giovannoni G. Autoaggressive immune mediated movement disorders. Adv Neurol 2005;96:320-335.
36. Pittock SJ, Lucchinetti CF, Lennon VA. Antineuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol 2003;53:580-587.
37. Ertle F, Behnisch W, Ali Al Mulla N, et al. Treatment of neuroblastoma related opsoclonus-myoclonus-ataxia syndrome with high dose dexamethasone pulses. Pediatr Blood Cancer 2007;45:365-608.
38. Yiu VW, Kovithavongs T, McGonigle LF, Ferreira P. Plasmapheresis as an effective treatment for opsoclonus-myoclonus syndrome. Pediatr Neurol 2001;24:72-74. (Pubitemid 32140941)
39. Armstrong MB, Robertson PL, Castle VP. Delayed, recurrent opsoclonus-myoclonus syndrome responding to plasmapheresis. Pediatr Neurol 2005;33:365-367.
40. Bell J, Moran C, Blatt J. Response to rituximab in a child with neuroblatoma and opsoclonus myoclonus. Pediatr Blood Cancer 2008;50:370-371.
41. Pittock SJ, Lucchinetti CF, Parisi JE, et al. Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol 2005;58:96-107.
42. Attarian H, Applebee G, von Lepel A. Paraneoplastic myoclonus with papillary thyroid carcinoma. Eur Neurol 2007;58:182-183. (Pubitemid 47585029)
43. Muehlschlegel S, Okun MS, Foote KD, Coco D, Yachnis AT, Fernandez HH. Paraneoplastic chorea with leukoencephalopathy presenting with obsessive-compulsive and behavioural disorder. Mov Disord 2005;20:1523-1527. (Pubitemid 43072665)
44. Kinirons P, Fulton A, Keoghan M, Brennan P, Farrell M. Paraneoplastic limbic encephalitis (PLE) and chorea associated with CRMP-5 neuronal antibody. Neurology 2003;61:1623-1624. (Pubitemid 37505596)
45. Martino D, Giovannoni G. Anti-basal Ganglia antibodies and their relevance to movement disorders. Curr Opin Neurol 2004;17:425-432. (Pubitemid 39071418)
46. Kujawa KA, Niemi VR, Tomasi MA, Mayer NW, Cochran E, Goetz CG. Ballistic-choreic movements as the presenting feature of renal cancer. Arch Neurol 2001;58:1133-1135. (Pubitemid 32660777)
47. Stich O, Jarius S, Kleer B, Rasiah C, Voltz R, Rauer S. Specific antibody index in the cerebrospinal fluid from patients with central and peripheral paraneoplastic neurological syndromes. J Neuroimmunol 2007;183:220-224. (Pubitemid 46204909)
48. Samii A, Dahlen DD, Spence AM, Maronian NC, Kraus EE, Lennon VA. Paraneoplastic movement disorder in a patient with non-Hodgkin's lymphoma and CRMP-5 autoantibody. Mov Disord 2003;18:1156-1158. (Pubitemid 38035387)
49. Sansing LH, Tuzun E, Ko MW, Baccon J, Lynch DR, Dalmau J. A patient with encephalitis associated with NMDA receptor antibodies. Nat Clin Pract Neurol 2007;3:291-296. (Pubitemid 46745476)
50. Croteau D, Owainati A, Dalmau J, Rogers LR. Response to cancer therapy in a patient with a paraneoplastic choreiform disorder. Neurology 2001;57:719-722. (Pubitemid 32783009)
51. Dalmau J, Graus F, Villarejo A, et al. Clinical analysis of anti- Ma2-associated encephalitis. Brain 2004;127:1831-1844. (Pubitemid 39061559)
52. Matsumoto L, Yamamoto T, Higashihara M, et al. Severe hypokinesia caused by anti-Ma2 encephalitis associated with bilateral intratubular germ cell neoplasm of the testes. Mov Disord 2007;22:728-731. (Pubitemid 46800149)
53. Pruss H, Voltz R, Flath B, et al. Anti-Ta associated paraneoplastic encephalitis with occult testicular intratubular germ cell neoplasia. J Neurol Neurosurg Psychiatry 2007;78:651-652. (Pubitemid 46853908)
54. Tan JH, Goh BC, Tambyah PA, Wilder-Smith E. Paraneoplastic progressive supranuclear palsy in a patient with B cell lymphoma. Parkinsonism Relat Disord 2005;11:187-191. (Pubitemid 40501405)
55. Fahn S, Brin MF, Dwork AJ, Weiner WJ, Goetz CG, Rajput AH. Case 1, 1996: rapidly progressive Parkinsonism, incontinence, impotency, and levodopa-induced moaning in a patient with multiple myeloma. Mov Disord 1996;11:298-310.
56. Golbe LI, Miller DC, Duvoisin RC. Paraneoplastic degeneration of the substantia nigra with dystonia and Parkinsonism. Mov Disord 1989;4:147-152. (Pubitemid 19128937)
57. Schluter E, Domm S, Erdag S. A case of rapidly progressive multiple system degeneration: morphological findings and pathogenic implications. Acta Neuropathol 2002;103:395-1300
58. Josephs KA, Ishizawa T, Tsuboi Y, Cookson N, Dickson DW. A clinicopathological study of vascular progressive supranuclear palsy: a multi-infarct disorder presenting as progressive supranuclear palsy. Arch Neurol 2002;59:1597-1601.
59. Meinck HM, Thompson PD. Stiff man syndrome and related conditions. Mov Disord 2002;17:853-866.
60. McHugh JC, Murray B, Renganathan R, Connolly S, Lynch T. GAD antibody positive stiff person syndrome in a patient with renal cell carcinoma. Mov Disord 2007;22:1343-1346. (Pubitemid 47325048)
61. Grimaldi LM, Martino G, Braghi S, Quattrini A, Furlan R, Bosi E, Comi G. Heterogeneity of autoantibodies in stiff man syndrome. Ann Neurol 1993;34:57-64. (Pubitemid 23188727)
62. Ishii A, Hayashi A, Ohkoshi N, Matsuno S, Shoji S. Progressive encephalomyelitis with rigidity associated with anti-amphiphysin antibodies. J Neurol Neurosurg Psychiatry 2004;75:661-662. (Pubitemid 38406678)
63. Levy LM, Levy-Reis I, Fijii M, Dalakis MC. Brain gamma aminobutyric acid changes in Stiff Person Syndrome. Arch Neurol 2005;62:970-974. (Pubitemid 40973459)
64. Sommer C, Weishaupt A, Brinkhoff J, et al. Paraneoplastic stiff-person syndrome: passive transfer to rats by means of IgG antibodies to amphiphysin. Lancet 2005;365:1406-1411. (Pubitemid 40523735)
65. Manto MU, Laute MA, Aguera M, Rogemond V, Pandolfo M, Honnorat J. Effects of anti-glutamic acid decarboxylase antibodies associated with neurological diseases. Ann Neuol 2007;61:544-551. (Pubitemid 47068136)
66. Dalakas MC. Advances in the pathogenesis and treatment of patients with Stiff Person Syndrome. Curr Neurol Neurosci Rep 2008;8:45-55.
67. Essalmi L, Meaux-Ruault N, Hafsaoui C, Gil H, Curlier E, Dupond JL. Stiff person syndrome with thymoma. Efficacy of thymectomy. Rev Med Interne 2007;28:627-630.
68. Wessig C, Klein R, Schneider MF, Toyka KV, Naumann M, Sommer C. Neuropathology and binding studies in anti-amphiphysin associated stiff person syndrome. Neurology 2003;61:195-198. (Pubitemid 36875300)
69. Newsom-Davis J. Neuromyotonia. Rev Neurol 2004;160:S85-S89.
70. Gutmann L, Gutmann L. Myokymia and Neuromyotonia. J Neurol 2004;251:138-142.
71. Hart IK, Maddison P, Newsom-Davis J, et al. Autoantibodies detected to expressed potassium channels are implicated in neuromyotonia. Ann Neurol 1997;41:238-246. (Pubitemid 27082105)
72. Hart IK, Maddison P, Newsom-Davis J, Vincent A, Mills KR. Phenotypic variants of peripheral nerve hyperexcitability. Brain 2002;125;1887-1895. (Pubitemid 34885715)
73. Caress JB, Abend WK, Preston DC, Logigian EL. A case of Hodgkins lymphoma producing neuromyotonia. Neurology 1997;49:258-259.
74. Zifko U, Drlcek U, Machacek E, et al. Syndrome of continuous muscle fiber activity and plasmacytoma with IgM paraproteinemia. Neurology 1994;44:560-561. (Pubitemid 24098165)
75. Hart IK, Waters C, Vincent A, et al. Autoantibodies detected to expressed potassium channels are implicated in neuromyotonia. Ann Neurol 1997;41:238-246. (Pubitemid 27082105)
76. Toepfer M, Schroeder M, Unger JM, Lochmüller H, Pongratz D, Müller-Felber W. Neuromyotonia, myoclonus, sensory neuropathyand cerebellar symptoms in a patient with antibodies to neuronal neucleoprotein antibodies (anti-Hu). Clin Neurol Neurosurg 1999;101:207-209.
77. Alessi G, De Reuck J, De Bleeker J, Vancayzeele S. Successful immunoglobulin treatment in a patient with neuromyotonia. Clin Neurol Neurosurg 2000;102;173-175.
78. Tormoehlen LM, Pascuzzi RM. Thymoma, myasthenia gravis and other paraneoplastic syndromes. Haematol Oncol Clin North Am 2008;22:509-526. (Pubitemid 351726408)
79. Blumberg D, Port JL, Weksler B, et al. Thymoma: a multivariate analysis of factors predicting survival. Ann Thorac Surg 1995;60:908-913.